SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2Article Published on 2022-12-012022-11-16 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome All participant BA.1 BA.2 Booster vaccine caused collected comparable composed coronavirus coronavirus disease COVID-19 Day Diagnosis dose elapsed had no Infection log median median age nasopharyngeal specimen omicron Omicron variant Outpatient Patient reached retrospective RNA SARS-CoV-2 SARS-CoV-2 RNA Support symptom onset TaqPath Thermo Fisher Scientific time Transmissibility upper respiratory tract URT vaccination schedule Vaccine vaccine dose Viral load Viral load. viral RNA load was used [DOI] 10.1002/jmv.28079 PMC 바로가기
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in miceArticle Published on 2022-11-022022-11-15 Journal: PLoS ONE [Category] SARS, 변종, 진단, [키워드] Activation Arm cellular COVID-19 disease demonstrated development disease Efficacy hamster humoral IgA immune Immunity immunization induce intramuscular intramuscularly intranasal intranasally Lower respiratory tract lung Lung pathology medical need memory B cell mice mucosal mucosal immune pandemic promote protective immunity public health rapid progress response resulting robust S-2P Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine Seroconversion Spike protein systemic immune response the SARS-CoV-2 Transmission unique upper respiratory tract Vaccine vaccine candidate variants viral clearance weight loss while [DOI] 10.1371/journal.pone.0272594 PMC 바로가기
Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Respiratory Medicine [Category] SARS, 변종, 치료기술, [키워드] accelerate Alpha assessment assumption Bayesian Cohort cohort study Community Contact correlation Course COVID-19 COVID-19 case determine diagnosed early diagnosis eight eligible enrolled Evidence Final Guidance Hierarchical High-resolution household index cases Infection infection control Infectious virus initial IQR Isolation kinetic Lateral flow device LFD median Older Onset participant PCR positive PCR-confirmed plaque-forming unit post-symptom onset Probability quantified real-world data recruitment reduced released RT-PCR SARS-CoV-2 Self-isolation sensitivity Seven study population suggested Support survival Symptom symptom onset Symptoms the median the SARS-CoV-2 to define Transmission upper respiratory tract variant viral growth Viral load viral replication Viral RNA viral RNA load viral shedding virus were assessed [DOI] 10.1016/S2213-2600(22)00226-0 PMC 바로가기
Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 OutpatientsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 치료기술, 치료제, [키워드] acting acute respiratory syndrome added Administered administration Amplicon sequencing analyses Analysis antibody Antiviral antiviral property antiviral strategy applied Bacteria benefit Care chills collected Combined coronavirus coronavirus disease COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients detectable Diagnosis diarrhea double-blind dried blood spot eligible evaluated Fever Health hospital Hospitalization infected with SARS-CoV-2 Lactobacillaceae lactobacilli Microbiome modulation multifactorial nasopharyngeal viral load nose-throat swab online questionnaire Outpatient Pain Patient per-protocol analysis Placebo placebo-controlled trial positive potential mechanism practitioners qPCR quantitative PCR Randomized reduce reducing reported reported symptom respiratory tract infection respiratory viral disease SARS-CoV-2 selected sequence severity significantly spray strain Symptom symptom resolution the patient the placebo group therapy Throat throat spray. Treatment Trial trials upper respiratory tract Vaccines variant Viral diseases viral infection Viral load was performed [DOI] 10.1128/spectrum.01682-22 PMC 바로가기
Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret ModelArticle Published on 2022-10-262022-11-15 Journal: mBio [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] acute respiratory syndrome Airborne transmission Analysis assessment Beta changes Comparative Contact coronavirus coronavirus 2 COVID-19 Critical Delta disease evaluate ferret ferrets genomic variant Heterologous highest histopathological homologous homologous or heterologous Human in vivo infection with SARS-CoV-2 inoculated lineages lowest Mild Model offered pandemic Particle pathogenicity provided Reinfection replicated Replication replication kinetics respiratory respiratory tract risk RNA SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strains SARS-CoV-2 variant Spread Strains Surveillance the spike protein the United State Transmissibility Transmission transmitted upper respiratory tract USA-WA1/2020 variant Variant. variants virulence virus virus virus infection virus load WA1 while [DOI] 10.1128/mbio.02421-22 PMC 바로가기
B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman PrimatesArticle Published on 2022-10-262022-11-16 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] addition Alpha animal model association B.1.351 Beta caused changes in Characteristics Chinese circulating Clinical signs contribute determine distribution drugs early stage Efficacy and safety elevated exhibited IFN-γ IL-17 Infection Inflammatory Inflammatory cytokine interferon gamma interleukin 17 investigated less Lower respiratory tract lung tissue mechanisms mutated Necrosis NHP NHPs nonhuman primate pathogenesis of SARS-CoV-2 pathogenic pathogenicity pathological changes primate provide pulmonary inflammation reduced replicated Research rhesus macaque SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants severe lung injury shedding spike-specific T-cell response strain Strains tissue TNF-α Transmission upper respiratory tract Vaccine variant variants of concern viral distribution viral shedding virulence virulence. virulent VoC VOCs were infected [DOI] 10.1128/spectrum.02263-22 PMC 바로가기
Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 VaccineArticle Published on 2022-10-252022-11-15 Journal: ACS Nano [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, [키워드] ACM acute respiratory syndrome adverse effect airway antibodies antibody antigen presenting cells artificial Beta Beta spike C57BL/6 cell membrane clinical symptom clinical trial component conditions coronavirus coronavirus disease COVID-19 CpG cross-neutralizing current delivery of cargo dendritic cells dose doses evaluate evaluated Formulation generate Generation Good hamster hamsters immune responses immunization immunogenic induce Infection initiated interval intranasal mice neutralize neutralizing antibody neutralizing responses New omicron Phase 1 polymersome Practice PROTECT reduction repeated Safety SARS-CoV-2 second serum IgG spike Spike protein Spike-based vaccine Support Toxicity upper respiratory tract Vaccine vaccine. variants viral clearance Viral load virus weight loss wild type [DOI] 10.1021/acsnano.2c06350 PMC 바로가기
Immunogenicity, Safety, and Anti-Viral Efficacy of a Subunit SARS-CoV-2 Vaccine Candidate in Captive Black-Footed Ferrets ( Mustela nigripes) and Their Susceptibility to Viral ChallengeArticle Published on 2022-10-042022-11-15 Journal: Viruses [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] Affect Anti-viral Antibody Response Antibody titer black-footed ferrets candidate challenge clinical disease correlated declined Efficacy experimental challenge ferret highest Human immunogenicity in vitro in vivo increase in indicate lack lung viral load mice morbidity Mortality mustelids pathogen populations potential risk pre-vaccination produced Protein purified Safety SARS-CoV-2 SARS-CoV-2 S1 serum subunit susceptibility transfer Trial unlikely upper respiratory tract vaccination vaccination. vaccinees viral replication was determined [DOI] 10.3390/v14102188 PMC 바로가기
COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 PeriodsArticle Published on 2022-10-032022-11-16 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, [키워드] addition age Antigen Asymptomatic booster children clinical symptom Community conducted cough COVID-19 COVID-19 symptom COVID-19 testing cross-sectional Delta Duration Evolution Fever first positive Fisher Health Isolation Latinx less loss of taste median myalgia negative test omicron outcome participant Participants Patient Period population immunity positive positive result positive test result Practitioner proportion public health Rapid remained repeated reported reported symptoms San Francisco SARS-COV-2 infection seeking Site sore throat Symptom symptom onset symptomatic symptomatic participant Symptoms Test tested Testing upper respiratory tract vaccination Vaccine variant Viral variants were used with COVID-19 worsening χ2 test [DOI] 10.1001/jamanetworkopen.2022.35844 PMC 바로가기
Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategyArticle Published on 2022-10-012022-11-15 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Administered airway boost Booster vaccine CAF®01 cationic clearance effective elicit elicited European evaluated HexaPro highlight Horizon IgA response immune response intranasal intranasal vaccine lower airway Lung pathology mucosal mucosal immune Neutralizing antibodies onward transmission Parenteral PROTECT protection regimen Research response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 transmission SARS-CoV-2. Serum neutralizing antibody severe disease spike supported Transmission trimer union upper airway upper airways upper respiratory tract Vaccine virus virus transmission [DOI] 10.1016/j.ebiom.2022.104248 PMC 바로가기